RecruitingPhase 3NCT07011719
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Arcus Biosciences, Inc.
- Principal Investigator
- Medical DirectorArcus Biosciences
- Intervention
- Casdatifan(drug)
- Enrollment
- 720 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (29)
- City of Hope - Phoenix Cancer Center, Goodyear, Arizona, United States
- City Of Hope National Medical Center, Duarte, California, United States
- University of California San Diego Moores Cancer Center, La Jolla, California, United States
- UCLA Hematology Oncology - 100 Med Plaza, Los Angeles, California, United States
- University of California San Diego Moores Cancer Center, San Diego, California, United States
- Yale University, New Haven, Connecticut, United States
- Piedmont Cancer Institute OneOncology, Atlanta, Georgia, United States
- Emory University - Atlanta, Atlanta, Georgia, United States
- City of Hope Cancer Center Atlanta, Newnan, Georgia, United States
- City of Hope - Chicago Cancer Center, Zion, Illinois, United States
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Norton Cancer Institute PARENT, Louisville, Kentucky, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07011719 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma